Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Failure of 500 mg of ceftriaxone to eradicate pharyngeal gonorrhoea, Australia.

Y Chen M, Stevens K, Tideman R, Zaia A, Tomita T, Fairley CK, Lahra M, Whiley D, Hogg G.

J Antimicrob Chemother. 2013 Jun;68(6):1445-7. doi: 10.1093/jac/dkt017. Epub 2013 Feb 6. No abstract available.

PMID:
23390207
2.

Persistence of Neisseria gonorrhoeae DNA following treatment for pharyngeal and rectal gonorrhea is influenced by antibiotic susceptibility and reinfection.

Bissessor M, Whiley DM, Fairley CK, Bradshaw CS, Lee DM, Snow AS, Lahra MM, Hocking JS, Chen MY.

Clin Infect Dis. 2015 Feb 15;60(4):557-63. doi: 10.1093/cid/ciu873. Epub 2014 Nov 3.

PMID:
25371490
3.

Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011.

Unemo M, Golparian D, Poto─Źnik M, Jeverica S.

Euro Surveill. 2012 Jun 21;17(25). pii: 20200.

4.

An audit of pharyngeal gonorrhoea treatment in a public sexual health clinic in Adelaide, South Australia.

Hustig A, Bell C, Waddell R.

Int J STD AIDS. 2013 May;24(5):399-400. doi: 10.1177/0956462412472792. Epub 2013 Jun 14.

PMID:
23970709
5.

Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg) or cefotaxime (500 mg), Sweden, 2013 and 2014.

Golparian D, Ohlsson A, Janson H, Lidbrink P, Richtner T, Ekelund O, Fredlund H, Unemo M.

Euro Surveill. 2014 Jul 31;19(30). pii: 20862. Erratum in: Euro Surveill. 2014;19(32):pii/20874.

PMID:
25108533
6.
7.

Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods.

Tapsall J, Read P, Carmody C, Bourne C, Ray S, Limnios A, Sloots T, Whiley D.

J Med Microbiol. 2009 May;58(Pt 5):683-7. doi: 10.1099/jmm.0.007641-0.

PMID:
19369534
8.

One confirmed and one suspected case of pharyngeal gonorrhoea treatment failure following 500mg ceftriaxone in Sydney, Australia.

Read PJ, Limnios EA, McNulty A, Whiley D, Lahra MM.

Sex Health. 2013 Nov;10(5):460-2. doi: 10.1071/SH13077.

PMID:
24028864
9.

Retrospective review of pharyngeal gonorrhea treatment failures in Alberta, Canada.

Gratrix J, Bergman J, Egan C, Drews SJ, Read R, Singh AE.

Sex Transm Dis. 2013 Nov;40(11):877-9. doi: 10.1097/OLQ.0000000000000033.

PMID:
24113412
10.

The outcome of oropharyngeal gonorrhoea treatment with different regimens.

Harry TC.

Int J STD AIDS. 2005 Jul;16(7):520. No abstract available.

PMID:
16004640
11.

Isolated pharyngeal Neisseria gonorrhoeae in heterosexual male contacts.

Thomson-Glover R, Brown R, Edirisinghe DN.

Int J STD AIDS. 2013 Dec;24(12):983-5. doi: 10.1177/0956462413491238. Epub 2013 Jul 22.

PMID:
23970625
12.

Comparison of Neisseria gonorrhoeae isolates from the genital tract and pharynx of two gonorrhea patients.

Saika T, Nishiyama T, Kanayama A, Kobayashi I, Nakayama H, Tanaka M, Naito S.

J Infect Chemother. 2001 Sep;7(3):175-9.

PMID:
11810580
13.

First cases of Neisseria gonorrhoeae resistant to ceftriaxone in Catalonia, Spain, May 2011.

Carnicer-Pont D, Smithson A, Fina-Homar E, Bastida MT; Gonococcus Antimicrobial Resistance Surveillance Working Group..

Enferm Infecc Microbiol Clin. 2012 Apr;30(4):218-9. doi: 10.1016/j.eimc.2011.11.010. Epub 2012 Jan 14. No abstract available.

PMID:
22244992
14.

Single dose 1 g ceftriaxone for urogenital and pharyngeal infection caused by Neisseria gonorrhoeae.

Muratani T, Inatomi H, Ando Y, Kawai S, Akasaka S, Matsumoto T.

Int J Urol. 2008 Sep;15(9):837-42. doi: 10.1111/j.1442-2042.2008.02100.x. Epub 2008 Jul 25.

15.

Multiple doses of cefodizime are necessary for the treatment of Neisseria gonorrhoeae pharyngeal infection.

Matsumoto T, Muratani T, Takahashi K, Ikuyama T, Yokoo D, Ando Y, Sato Y, Kurashima M, Shimokawa H, Yanai S.

J Infect Chemother. 2006 Jun;12(3):145-7.

PMID:
16826347
16.

Should urologists care for the pharyngeal infection of Neisseria gonorrhoeae or Chlamydia trachomatis when we treat male urethritis?

Hamasuna R, Takahashi S, Uehara S, Matsumoto T.

J Infect Chemother. 2012 Jun;18(3):410-3. doi: 10.1007/s10156-011-0355-6.

PMID:
22302695
17.

UK national guideline for the management of gonorrhoea in adults, 2011.

Bignell C, Fitzgerald M; Guideline Development Group.; British Association for Sexual Health and HIV UK..

Int J STD AIDS. 2011 Oct;22(10):541-7. doi: 10.1258/ijsa.2011.011267.

PMID:
21998172
18.

Ceftriaxone-resistant Neisseria gonorrhoeae, Japan.

Ohnishi M, Saika T, Hoshina S, Iwasaku K, Nakayama S, Watanabe H, Kitawaki J.

Emerg Infect Dis. 2011 Jan;17(1):148-9. doi: 10.3201/eid1701.100397. No abstract available.

19.

Efficacy of 250 mg trospectomycin sulfate i.m. vs. 250 mg ceftriaxone i.m. for treatment of uncomplicated gonorrhea.

Rompalo AM, Colletta L, Caine VA, Linnemeier P, Neumann T, Hook EW 3rd, Jones RB.

Sex Transm Dis. 1994 Jul-Aug;21(4):213-6.

PMID:
7974072
20.

Trends of sexually transmitted diseases and antimicrobial resistance in Neisseria gonorrhoeae.

Matsumoto T.

Int J Antimicrob Agents. 2008 Feb;31 Suppl 1:S35-9. doi: 10.1016/j.ijantimicag.2007.08.029.

PMID:
18164598

Supplemental Content

Support Center